uniQure Archives

News and Trends 28 Mar 2017

Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?

Pharma would seemingly best biotech in any competition. A few CEOs explain why it left the honor of “The First Gene Therapy” to biotech. On July 20, 2012, the western world’s first gene therapy, Glybera, received marketing authorization from the EMA. The treatment was designed and developed by uniQure as one-off treatment for Lipoprotein Lipase Deficiency (LPLD), a […]

March 28, 2017 - 5 minutesmins - By Evelyn Warner

News and Trends 28 Feb 2017

It’s Global Rare Disease Day! What Cures is Biotech Cooking Up?

We’ve compiled a list of some of the latest advances of biotech in the field of rare disease to contribute to Rare Disease Day 2017. The European Organization for Rare Diseases (EURORDIS) is once again coordinating Rare Disease Day, which takes place on the last day of February every year. The aim is to raise awareness of […]

February 28, 2017 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 30 Jan 2017

The FDA gives Fast Track Priority to uniQure’s Hemophilia B Gene Therapy

UniQure has received Breakthrough Therapy Designation from the FDA, granting fast track to its gene therapy for hemophilia B. UniQure is one of the companies leading the development of gene therapy for hemophilia. Now, the FDA has granted Breakthrough Therapy Designation to its candidate AMT-060 for hemophilia B. This is awarded to selected therapies that have […]

January 30, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 11 Jan 2017

UPDATE: The 5 Hottest European Biotechs in 2017 according to JP Morgan

The world’s biggest biotech investor conference, hosted by JP Morgan, is now underway in San Francisco, and European companies are putting up a strong showing. Here are those (in chronological order) who made the cut to present at this invite-only event. We’ll update the post as companies present! While uniQure has hit a number of rough […]

January 11, 2017 - 3 minutesmins - By Evelyn Warner

Interview 9 Jan 2017

After a Rough Year, uniQure CMO discusses a Comeback

Last year was a bad year for biotech as an industry, but it was particularly bad for uniQure. Here’s what its CMO has to say about the company’s recovery. After giving the world its first gene therapy, uniQure has hit a series of rough patches since it rose to stardom as one of biotech’s success stories. […]

January 9, 2017 - 4 minutesmins - By Evelyn Warner

News and Trends 20 Dec 2016

UPDATE: UniQure keeps afloat with a New CEO and More Clinical Data

UniQure’s gene therapy for Hemophilia B is performing well in clinical trials, but the company faces many challenges with its current financial situation. Can it manage to make it to the market? UniQure is famous for launching Glybera, the first globally approved gene therapy, which has been a commercial failure. The company is now indefinitely missing […]

December 20, 2016 - 3 minutesmins - By Clara Rodríguez Fernández

News and Trends 17 Nov 2016

UniQure takes an axe to its Pipeline and Workforce in new R&D Strategy

UniQure just announced a new R&D plan designed to save up to €27M over the next two years. Will the new strategy be enough to pull it out of its down spiral? UniQure is a Dutch biotech famous for launching Glybera, the first commercial gene therapy worldwide. However, the huge price of the treatment has […]

November 17, 2016 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 16 Nov 2016

Cell Therapies: Is Commercialization holding back a Breakthrough?

How far away is biotech from a breakthrough with cell and gene therapy? While these therapies have the potential to be the most effective on the market, they are still a long way away from that point, according to a pair of expert panels at BIO Europe last week. Everyone in cell therapy knows the […]

November 16, 2016 - 4 minutesmins - By Evelyn Warner

News and Trends 4 Nov 2016

Roche hits a Speed Bump on the way to a Hemophilia Cure

The Swiss pharma is gearing up for a battle with Novo Nordisk in Hemophilia, but a safety setback might slow its progress. There is a ‘bloody’ battle in Europe that no one is talking about: who will claim the next Hemophilia blockbuster drug? Roche has established itself as a force to be reckoned with via […]

November 4, 2016 - 4 minutesmins - By Evelyn Warner

News and Trends 29 Jul 2016

Gene Therapy for severe Hemophilia has new Phase I/II Results

uniQure has new data from the Phase I/II trial of its gene therapy for Hemophilia B, a rare genetic disorder. After 9 months, the therapy maintains 75% reduction of transfusions. A good sign for the therapy’s durability. Although quite rare (1 in 20,000 male births), Hemophilia B is famous for being spread in European royal […]

July 29, 2016 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 11 Jul 2016

How to build a Successful Biotech company in Europe with Joern Aldag

Joern Aldag is one of the impressive Biotech leaders in Europe. Hearing him at our Refresh conference made me think of a new type of article we could publish: a detailed summary of the lessons learned from such a very rich career. Here’s the first of such a piece. Aldag was just appointed CEO of […]

July 11, 2016 - 6 minutesmins - By Philip Hemme

News and Trends 6 May 2016

This Dutch Gene Therapy is on the shelf and seems to Work. But nobody is buying…

uniQure‘s Glybera was approved in Europe in 2012, making it the first gene therapy on the market in the West. But so far this €1M therapy has only been bought once… The approval of Glybera was an important milestone for Biotech. After years of being deemed too risky (after the death of Jesse Gelsinger in 1999), a […]

May 6, 2016 - 3 minutesmins - By Denise Neves Gameiro

Resources

Categories

Swiss biotech going strong in 2024: 18 companies to put on your radar

The ABC of biotech startup funding

Approaches

Therapeutic areas

Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR

Special Olympics: How is biotechnology revolutionizing sports performance worldwide?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us